Technology Bundle ID: TAB-2753

HIV-1 BED: A Simple Serological Assay for Detecting Recent Infection and Estimating Incidence of Multiple, Worldwide HIV-1 Subtypes

Request More Info
Licensing Contact:
Chou-Pong Pau (CDC), Steve McDougal (CDC)
Development Stage: 
Pre-Clinical (in vitro)
Development Status: 

In vitro data available

Institute or Center: 

This CDC developed invention is a simple enzyme immunoassay that detects increasing levels of anti-HIV-IgG after seroconversion and can be used for detection of HIV-1 infection. The assay, termed IgG-Capture BED-EIA, incorporates a branched peptide derived from 3 different subtypes to allow equivalent detection of antibodies of different subtypes. The competitive format of the assay allows detection of increasing proportion of HIV-1 IgG for almost 2 years after seroconversion. This is different from what is normally observed in a conventional EIA (with antigen coated plates) that plateaus soon after seroconversion. This assay will be important for HIV prevention activities, targeting resources, and evaluation of ongoing interventions.

  • HIV clinical serodiagnostics
  • Informing clinical decision-making
  • Public health/HIV monitoring programs and incidence surveillance
  • Ready for commercialization
  • Simple and high-throughput capable
  • Detects HIV-1 subtypes prevalent in N. America, Europe, Japan, Thailand, Australia, and also central and E. Africa


EIR Application

Research Tool – Patent protection is not being pursued for this technology.

Research Tools - Patent protection is not being pursued for these technologies.


Dobbs T, et al.
PMID 15184443
Dobbs T, et al.
PMID 21832016
Nesheim S, et al.
PMID 15989458
Parekh BS, et al.
PMID 11860677
Parekh BS, et al.
PMID 20954834


Jan 29, 2014

Data Source: